Online citations, reference lists, and bibliographies.

Clinical Research Methodologies In Diagnosis And Staging Of Patients With Peritoneal Carcinomatosis.

P. Jacquet, P. Sugarbaker
Published 1996 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The following methodologies may be strictly applied to quantitatively evaluate patients with peritoneal carcinomatosis or sarcomatosis in regard to disease progression or regression: (1) Preoperative CT scan and the intraoperative assessment of cancer extent is analyzed region by region (AR-0-12) and an estimation of tumor volume (V0-V3) is evaluated according to the standardized scoring system previously described. At laparotomy, the volume of tumor nodules to adjacent organs, the viscosity (mucinous vs. solid) of tumor mass, and the pattern of distribution is assessed. (2) Radiologic abdominopelvic CT parameters that predict an incomplete cytoreduction are focal obstructions of bowel by CT assessment and tumor involvement of proximal ileum (AR-11). (3) The extent of prior surgical interventions (PS-1 through PS-3) must be recorded because aggressive deep dissections without perioperative chemotherapy severely jeopardize the possibility for complete cytoreduction. (4) Many tumor samples should be sent for histopathologic analysis. A proportion of mucin > 80% confirms a mucinous cancer. The malignant differentiation of cells, stroma morphology, the presence of signet ring cells, and evidence of invasion are used to grade cancers as mucinous tumor grade 0-3 (MTG-0 through MTG-3). (5) Once the cytoreductive procedure is accomplished, the surgeon estimates the residual volume of disease. (6) Objective response criteria from CT scan, tumor marker, and radiolabeled monoclonal antibody studies are necessary in a regular follow-up schedule.



This paper is referenced by
10.1007/s00259-016-3347-z
FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei
J. Dubreuil (2016)
10.33878/2073-7556-2017-0-1-53-58
THE ROLE OF CYTOREDUCTIVE SURGERY (CRS) AND INTRAPERITONEAL INTRAOPERATIVE CHEMOTHERAPY (IIC) IN THE TREATMENT OF PERITONEAL CARCINOMATOSIS FROM COLORECTAL ORIGIN
Yu. A. Shelygin (2017)
10.1245/s10434-020-08242-x
Prognostic Impact of Curative Resection for Peritoneal Recurrence of Colorectal Cancer
Ken Imaizumi (2020)
10.1177/000313481708300212
The Efficacy of Dextran-40 as a Venous Thromboembolism Prophylaxis Strategy in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Jason M. Foster (2017)
10.1186/s12885-019-5640-2
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II)
W. Koemans (2019)
10.1007/s00432-014-1633-3
The importance of gender in patients with peritoneal metastases of appendiceal origin treated by cytoreduction and intraperitoneal chemotherapy: an analysis of 257 consecutive patients from an Australian centre
L. Ung (2014)
10.1097/MD.0000000000007306
Experiences with cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy in Taiwan
M C Hsieh (2017)
10.11648/J.ASS.20130102.11
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Advanced Ovarian Carcinoma: Initial Experience in Mexico
Horacio Noé López-Basave (2013)
10.1186/s12957-017-1114-7
Gastric perforation following cytoreductive surgery and perioperative intraperitoneal chemotherapy: a case series of six
L. S. Kyang (2017)
10.1016/j.annpat.2014.01.012
[Peritoneal pseudomyxoma: an overview emphasizing pathological assessment and therapeutic strategies].
Peggy Dartigues (2014)
10.1245/s10434-019-07452-2
Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC
W. Graf (2019)
10.1016/j.ejso.2018.01.009
Peritoneal metastases invading the seminal vesicles: Radiologic appearance and outcome of treatment.
Paul H Sugarbaker (2018)
10.1186/s13048-020-00625-8
Ovarian cancer subtypes and survival in relation to three comprehensive imaging parameters
Hanna Sartor (2020)
10.1245/s10434-020-08535-1
Impact of Mucin Cellularity and Distribution on Survival in Newly Diagnosed Patients with Low-Grade Appendiceal Mucinous Neoplasm Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Andrei Nikiforchin (2020)
10.1080/00015458.2015.11681109
Simultaneous Parenchyma-Preserving Liver Resection, Cytoreductive Surgery and Intraperitoneal Chemotherapy for Stage IV Colorectal Cancer
L.F. Abreu de Carvalho (2015)
10.1080/00015458.2018.1436797
Urological approach for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a clinical care center
Carlos Gustavo Trujillo (2018)
10.1002/bjs.10527
Evaluation of the peritoneal carcinomatosis index with CT and MRI
A. Dohan (2017)
10.1245/s10434-007-9350-7
Selection of Patients with Colorectal Peritoneal Carcinomatosis for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy
T. D. Y. B. Mbbs (2007)
10.1007/s00268-009-0059-6
Significance of Lymph Node Metastasis in Patients with Colorectal Cancer Peritoneal Carcinomatosis
T. Chua (2009)
10.1245/s10434-012-2627-5
Significance of Serum Tumor Marker Levels in Peritoneal Carcinomatosis of Appendiceal Origin
P. Wagner (2012)
Prognostic factors and outcomes of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer - A single tertiary institution experience.
M. Kocić (2016)
10.1016/j.suc.2017.01.013
Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis.
B. Hall (2017)
10.1080/00015458.2010.11680598
How Should we Treat Mucinous Appendiceal Neoplasm ? By Laparoscopy or Laparotomy ?: A Case Report
G. Liberale (2010)
10.1007/s00268-009-0281-2
Morbidity and Mortality of 109 Consecutive Cytoreductive Procedures with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Performed at a Community Hospital
Alexander G. Kerscher (2009)
10.1371/journal.pone.0083921
The Role of Non-Curative Surgery in Incurable, Asymptomatic Advanced Gastric Cancer
Ming-Ming He (2013)
10.1007/978-88-470-5711-1_24
Main Topics of Discussion and New Trends
Angelo Di Giorgio (2015)
10.1245/s10434-015-4989-y
Importance of Absent Neoplastic Epithelium in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
M. Enblad (2015)
10.1097/SLA.0000000000001723
A Perioperative Clinical Pathway Can Dramatically Reduce Failure-to-rescue Rates After Cytoreductive Surgery for Peritoneal Carcinomatosis: A Retrospective Study of 666 Consecutive Cytoreductions
G Passot (2017)
Colorectal and appendiceal peritoneal metastases : From population studies to genetics
M. Enblad (2018)
10.1245/s10434-014-4111-x
Institutional Learning Curve of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Malignancies
Patricio M. Polanco (2014)
10.1016/j.ejso.2012.07.009
Outcome differences between debulking surgery and cytoreductive surgery in patients with Pseudomyxoma peritonei.
Hanna Andréasson (2012)
10.3978/j.issn.2078-6891.2012.046
Effectiveness of early and aggressive administration of fresh frozen plasma to reduce massive blood transfusion during cytoreductive surgery.
A. Saxena (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar